FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912257566> ?p ?o ?g. }

• W2912257566 endingPage "155" @default.
• W2912257566 startingPage "149" @default.
• W2912257566 abstract "Abstract Background & aims Chlorcyclizine HCl (CCZ) is a piperazine-class antihistamine with anti-hepatitis C virus (HCV) activity in vitro and in vivo. In a first-in-humans study for HCV, we evaluated the antiviral effects and safety of CCZ±ribavirin (RBV), characterized pharmacokinetic (PK) and viral kinetic (VK) patterns, and provide insights into CCZs mode of action against HCV. Methods Chronic HCV patients were randomized to CCZ (75 mg twice daily) or CCZ+weight-based RBV (1000/1200 mg daily) for 28 days. Therapy started with a loading dose of CCZ 150 mg ± RBV. Serial assessments of safety, liver tests, PK and VK markers were obtained. Results 24 HCV patients were treated; 54% male, median age 56 years, median HCV RNA 6.30 log IU/ml, without baseline differences between groups. At the end of therapy, subjects treated with CCZ monotherapy did not show any significant or sustained reduction in viremia (p = 0.69), whereas 7/12 (58%) subjects treated with CCZ+RBV had a >3-fold decline in HCV RNA. Subjects who responded demonstrated monophasic (n = 2), biphasic (n = 2) and triphasic (n = 3) VK responses. Contrary to historical RBV monotherapy response, CCZ+RBV demonstrated a continued viral decline suggesting a possible synergistic effect of CCZ+RBV. Mathematical modeling predicts a median effectiveness of CCZ+RBV in blocking viral production (e) of 59% (Interquartile range, IQR: 50%) and blocking infection (η) of 78% (IQR: 23%). Adverse events (AEs) were mild-moderate without treatment discontinuations for AEs. Conclusions In this human pilot study, CCZ demonstrated some anti-HCV effects, mostly in combination with RBV. More potent CCZ derivatives with optimal PK features may be more suitable for future therapeutic development. ClinicalTrials.gov number: NCT02118012." @default.
• W2912257566 created "2019-02-21" @default.
• W2912257566 creator A5001196534 @default.
• W2912257566 creator A5017730028 @default.
• W2912257566 creator A5023443595 @default.
• W2912257566 creator A5025623011 @default.
• W2912257566 creator A5031887990 @default.
• W2912257566 creator A5036261777 @default.
• W2912257566 creator A5036659462 @default.
• W2912257566 creator A5041881672 @default.
• W2912257566 creator A5042241497 @default.
• W2912257566 creator A5068056560 @default.
• W2912257566 creator A5068960425 @default.
• W2912257566 creator A5071899808 @default.
• W2912257566 creator A5072184625 @default.
• W2912257566 creator A5077195292 @default.
• W2912257566 date "2019-03-01" @default.
• W2912257566 modified "2023-10-16" @default.
• W2912257566 title "A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C" @default.
• W2912257566 cites W186020890 @default.
• W2912257566 cites W1967080996 @default.
• W2912257566 cites W1968376947 @default.
• W2912257566 cites W1969720994 @default.
• W2912257566 cites W1976110218 @default.
• W2912257566 cites W1980714008 @default.
• W2912257566 cites W1992785718 @default.
• W2912257566 cites W2005888814 @default.
• W2912257566 cites W2013320805 @default.
• W2912257566 cites W2017496311 @default.
• W2912257566 cites W2042063943 @default.
• W2912257566 cites W2043519223 @default.
• W2912257566 cites W2072445394 @default.
• W2912257566 cites W2089033703 @default.
• W2912257566 cites W2107020066 @default.
• W2912257566 cites W2108492672 @default.
• W2912257566 cites W2138784029 @default.
• W2912257566 cites W2143549975 @default.
• W2912257566 cites W2146768477 @default.
• W2912257566 cites W2180878619 @default.
• W2912257566 cites W2286811631 @default.
• W2912257566 cites W2328909886 @default.
• W2912257566 cites W2412963213 @default.
• W2912257566 cites W2578013986 @default.
• W2912257566 cites W2772492785 @default.
• W2912257566 cites W2793096768 @default.
• W2912257566 cites W971519378 @default.
• W2912257566 doi "https://doi.org/10.1016/j.antiviral.2019.01.017" @default.
• W2912257566 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6402797" @default.
• W2912257566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30711416" @default.
• W2912257566 hasPublicationYear "2019" @default.
• W2912257566 type Work @default.
• W2912257566 sameAs 2912257566 @default.
• W2912257566 citedByCount "6" @default.
• W2912257566 countsByYear W29122575662019 @default.
• W2912257566 countsByYear W29122575662020 @default.
• W2912257566 countsByYear W29122575662022 @default.
• W2912257566 crossrefType "journal-article" @default.
• W2912257566 hasAuthorship W2912257566A5001196534 @default.
• W2912257566 hasAuthorship W2912257566A5017730028 @default.
• W2912257566 hasAuthorship W2912257566A5023443595 @default.
• W2912257566 hasAuthorship W2912257566A5025623011 @default.
• W2912257566 hasAuthorship W2912257566A5031887990 @default.
• W2912257566 hasAuthorship W2912257566A5036261777 @default.
• W2912257566 hasAuthorship W2912257566A5036659462 @default.
• W2912257566 hasAuthorship W2912257566A5041881672 @default.
• W2912257566 hasAuthorship W2912257566A5042241497 @default.
• W2912257566 hasAuthorship W2912257566A5068056560 @default.
• W2912257566 hasAuthorship W2912257566A5068960425 @default.
• W2912257566 hasAuthorship W2912257566A5071899808 @default.
• W2912257566 hasAuthorship W2912257566A5072184625 @default.
• W2912257566 hasAuthorship W2912257566A5077195292 @default.
• W2912257566 hasBestOaLocation W29122575662 @default.
• W2912257566 hasConcept C111919701 @default.
• W2912257566 hasConcept C124978682 @default.
• W2912257566 hasConcept C126322002 @default.
• W2912257566 hasConcept C159047783 @default.
• W2912257566 hasConcept C168563851 @default.
• W2912257566 hasConcept C177713679 @default.
• W2912257566 hasConcept C18903297 @default.
• W2912257566 hasConcept C2522874641 @default.
• W2912257566 hasConcept C3020491458 @default.
• W2912257566 hasConcept C41008148 @default.
• W2912257566 hasConcept C519536355 @default.
• W2912257566 hasConcept C535046627 @default.
• W2912257566 hasConcept C71924100 @default.
• W2912257566 hasConcept C86803240 @default.
• W2912257566 hasConceptScore W2912257566C111919701 @default.
• W2912257566 hasConceptScore W2912257566C124978682 @default.
• W2912257566 hasConceptScore W2912257566C126322002 @default.
• W2912257566 hasConceptScore W2912257566C159047783 @default.
• W2912257566 hasConceptScore W2912257566C168563851 @default.
• W2912257566 hasConceptScore W2912257566C177713679 @default.
• W2912257566 hasConceptScore W2912257566C18903297 @default.
• W2912257566 hasConceptScore W2912257566C2522874641 @default.
• W2912257566 hasConceptScore W2912257566C3020491458 @default.
• W2912257566 hasConceptScore W2912257566C41008148 @default.
• W2912257566 hasConceptScore W2912257566C519536355 @default.
• W2912257566 hasConceptScore W2912257566C535046627 @default.

• next